Shares of Traws Pharma, Inc. (NASDAQ:TRAW – Get Free Report) have been assigned an average rating of “Reduce” from the five ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $1.00.
Several equities analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Traws Pharma in a report on Wednesday, August 26th. HC Wainwright reissued a “neutral” rating and set a $1.00 price objective on shares of Traws Pharma in a report on Tuesday, August 18th.
Get Our Latest Stock Analysis on TRAW
Traws Pharma Price Performance
Traws Pharma (NASDAQ:TRAW – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03. On average, equities analysts expect that Traws Pharma will post -1.20 earnings per share for the current fiscal year.
Traws Pharma Company Profile
Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.
Further Reading
- Five stocks we like better than Traws Pharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
